biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by GlassHalfEmptyon Jun 21, 2018 11:38am

108 Views

Post# 28205818

RE:RE:RE:RE:RE:Key event

"....down the road of misdirection."
Ha! Ha! I love that! Brought a smile to my face.

With regards to your item 3 I for one would be voting no for any reverse split.
Usually they don't work out well for long time existing shareholders.
And I am not in favout of a company going to the NAS before they have the goods.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading